Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of immunotherapy
combined with cetuximab and platinum neoadjuvant therapy in patients with resectable locally
advanced hypopharyngeal cancer. Participants will receive three cycles of TPC neoadjuvant
therapy (toripalimab+ cetuximab + platinum), radical surgery (laryngeal preservation surgery
if possible), and sequential (chemo)radiotherapy treatment after surgery. This trial aims to
answer the following questions:
1. pCR rate
2. MPR rate, ORR, LPR/DFS/OS rare at 1 and 2 years
3. Safety and quality of life